Misplaced Pages

Gatipotuzumab is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), enabling it to differentiate between tumor MUC1 and non-tumor MUC1 epitopes. Gatipotuzumab is being developed by Glycotope GMBH and is undergoing a phase II clinical trial for ovarian cancer.

References

1. "Gatipotuzumab". Drug Dictionary. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services.
2. "Gatipotuzumab – Our first-in-class GlycoBody against the novel tumor-specific TA-MUC1 epitope". Glycotope GmbH.
3. Clinical trial number NCT01899599 for "PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer " at ClinicalTrials.gov

External links

• "Gatipotuzumab". Drug Information Portal. U.S. National Library of Medicine.

• Medicine

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Experimental monoclonal antibodies
• Monoclonal antibody stubs